Small interfering RNA (siRNA) is a form of genetic medicine that can silence or knock out any overexpressed genes in disease.It's also called short interfering RNA.These rnas are widely used to assess the specific contributions of genes to a variety of cell phenotypes, including apoptosis, pancreatic bird signaling, cytokinesis, and cell differentiation.They are used to identify novel pathways and have a meaningful impact on the identification of targets for several diseases (such as AIDS, cancer and hepatitis) and cellular processes.The mechanism of action of siRNA involves introducing it into cells.SiRNA sequences should be designed to match the short regions of the target gene.Small interfering rnas are processed by the cell's own enzymes to eliminate the mRNA of the target gene, thereby preventing overexpression of the pathogenic gene.It is based on the natural response of cells when they detect genetic abnormalities or infections.It has some advantages over the different types of therapies currently available, such as target specificity, reduced secondary effects, and high specificity.The preclinical development duration of small interfering RNA compounds (about 15 to 24 months) is shorter than that of monoclonal antibodies (about 27 to 50 months) or other traditional small molecules (about 42 to 66 months).The shortening of preclinical stage is attributed to the rational design of RNA.The design includes mathematical algorithms assembled in software to select the most appropriate RNA sequence to silence specific genetic targets.They are usually more effective than other traditional medicines.SiRNA therapy includes liposome-based systemic therapy and nanoparticle based systemic therapy.Liposome-based systems are associated with liver-targeted pharmacokinetics, which limits the therapeutic potential of siRNA therapy to other common liver diseases, such as hepatocellular carcinoma, hepatitis, and hypercholesterolemia.
This report contains market size and forecasts of Small Interfering RNA (siRNA) Therapeutics in Global, including the following market information:
Global Small Interfering RNA (siRNA) Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Small Interfering RNA (siRNA) Therapeutics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Liposome Based Systemic Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Small Interfering RNA (siRNA) Therapeutics include GE, Horizon Discovery, Thermo Scientific, OPKO Health, AInylam Pharmaceuticals, Arrowhead Research, Sanofi Genzyme, Genecon Biotechnologies and Arbutus Biopharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Small Interfering RNA (siRNA) Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Small Interfering RNA (siRNA) Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Small Interfering RNA (siRNA) Therapeutics Market Segment Percentages, by Type, 2021 (%)
Liposome Based Systemic Therapy
Nanoparticle Based Systemic Therapy
Other
Global Small Interfering RNA (siRNA) Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Small Interfering RNA (siRNA) Therapeutics Market Segment Percentages, by Application, 2021 (%)
Hospital
Research Institutions
Pharmaceutical and Biotechnology Companies
Academic Institutions
Other
Global Small Interfering RNA (siRNA) Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Small Interfering RNA (siRNA) Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Small Interfering RNA (siRNA) Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Small Interfering RNA (siRNA) Therapeutics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
GE
Horizon Discovery
Thermo Scientific
OPKO Health
AInylam Pharmaceuticals
Arrowhead Research
Sanofi Genzyme
Genecon Biotechnologies
Arbutus Biopharma
Silent Therapeutics
Sylentis